Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 3
2010 6
2011 3
2012 2
2013 7
2014 5
2015 3
2016 2
2017 1
2018 2
2019 3
2020 8
2021 14
2022 7
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. Among authors: leroux roels i. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, Andrews CP, Kerwin E, David MP, Fissette L, Vanden Abeele C, Collete D, de Heusch M, Salaun B, De Schrevel N, Koch J, Verheust C, Dezutter N, Struyf F, Mesaros N, Tica J, Hulstrøm V. Leroux-Roels I, et al. J Infect Dis. 2023 Mar 28;227(6):761-772. doi: 10.1093/infdis/jiac327. J Infect Dis. 2023. PMID: 35904987 Free PMC article. Clinical Trial.
Selective digestive decontamination - Pro.
De Waele JJ, Leroux-Roels I, Depuydt P. De Waele JJ, et al. Among authors: leroux roels i. Intensive Care Med. 2023 Aug;49(8):979-981. doi: 10.1007/s00134-023-07100-0. Epub 2023 May 20. Intensive Care Med. 2023. PMID: 37209122 No abstract available.
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Ison MG, et al. Among authors: leroux roels i. Clin Infect Dis. 2024 Jan 22:ciae010. doi: 10.1093/cid/ciae010. Online ahead of print. Clin Infect Dis. 2024. PMID: 38253338
Multidrug-resistant bacteria in ICU: fact or myth.
De Waele JJ, Boelens J, Leroux-Roels I. De Waele JJ, et al. Among authors: leroux roels i. Curr Opin Anaesthesiol. 2020 Apr;33(2):156-161. doi: 10.1097/ACO.0000000000000830. Curr Opin Anaesthesiol. 2020. PMID: 31904697 Review.
Caught on tape.
Vandenabeele L, Coppens G, Leroux-Roels I, Hindryckx P. Vandenabeele L, et al. Among authors: leroux roels i. Gastrointest Endosc. 2016 Mar;83(3):665; discussion 666. doi: 10.1016/j.gie.2015.08.055. Epub 2015 Sep 5. Gastrointest Endosc. 2016. PMID: 26348549 No abstract available.
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study.
Narejos Pérez S, Ramón Torrell JM, Põder A, Leroux-Roels I, Pérez-Breva L, Steenackers K, Vandermeulen C, Meisalu S, McNally D, Bowen JST, Heer A, Beltran Martinez A, Helman LL, Arora A, Feldman RG, Patel R, Shah A, Devadiga R, Damaso S, Matthews S, Pirçon JY, Luyts D. Narejos Pérez S, et al. Among authors: leroux roels i. Open Forum Infect Dis. 2023 Mar 1;10(4):ofad111. doi: 10.1093/ofid/ofad111. eCollection 2023 Apr. Open Forum Infect Dis. 2023. PMID: 37065988 Free PMC article.
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults.
Bézay N, Hochreiter R, Kadlecek V, Wressnigg N, Larcher-Senn J, Klingler A, Dubischar K, Eder-Lingelbach S, Leroux-Roels I, Leroux-Roels G, Bender W. Bézay N, et al. Among authors: leroux roels i. Lancet Infect Dis. 2023 Oct;23(10):1186-1196. doi: 10.1016/S1473-3099(23)00210-4. Epub 2023 Jul 4. Lancet Infect Dis. 2023. PMID: 37419129 Clinical Trial.
73 results